Related Experiment Video
Updated: Apr 5, 2026
08:40
Quantitation of Protein Expression and Co-localization Using Multiplexed Immuno-histochemical Staining and Multispectral Imaging
Published on: April 8, 2016
13.5K
Single tumor imaging with multiple antibodies targeting different antigens
Yujing Sun1, Girja Shukla1, Stephanie C Pero1
1Department of Surgery, Vermont Cancer Center, University of Vermont College of Medicine, Burlington, VT, USA.
Biotechniques
|August 27, 2015
Summary
Researchers simultaneously tracked two breast cancer antibodies, anti-ErbB2 and anti-EpCAM, in mice using near-infrared imaging. This method aids in designing combination antibody therapies and understanding their interactions, pharmacokinetics, and side effects.
Area of Science:
- Oncology
- Immunology
- Biomedical Imaging
Background:
- Antibodies are crucial in cancer treatment, with combination therapies showing promise for improved outcomes.
- Targeting multiple cancer markers can enhance therapeutic efficacy.
- Understanding the in vivo behavior of multiple antibodies is essential for effective treatment design.
Purpose of the Study:
- To develop and validate a method for simultaneous in vivo assessment of two breast cancer-targeting antibodies.
- To evaluate the distribution of fluorescently labeled anti-ErbB2 and anti-EpCAM antibodies in a breast cancer xenograft model.
- To provide a foundation for optimizing combination antibody dosing and predicting pharmacokinetic interactions.
Main Methods:
- Breast cancer xenograft models were established in mice.
- Two antibodies, anti-ErbB2 and anti-EpCAM, were labeled with distinct infrared fluorescence dyes.
- Near-infrared (NIR) fluorescence imaging was employed to determine the in vivo distribution of both antibodies simultaneously.
Main Results:
- The simultaneous detection and assessment of both labeled antibodies in the mouse xenograft model were successful.
- The near-infrared fluorescence imaging system effectively visualized the distribution of anti-ErbB2 and anti-EpCAM antibodies.
- The study demonstrated the feasibility of tracking multiple antibodies concurrently in vivo.
Conclusions:
- Simultaneous in vivo imaging of multiple antibodies is achievable and valuable for preclinical cancer research.
- This approach can guide the design of combination antibody dosing strategies.
- The method facilitates the identification of potential pharmacokinetic interactions and side effects of combined antibody therapies.
